Barclays PLC Sells 25,232 Shares of IDEXX Laboratories, Inc. $IDXX

Barclays PLC trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 211,438 shares of the company’s stock after selling 25,232 shares during the quarter. Barclays PLC’s holdings in IDEXX Laboratories were worth $143,044,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of IDXX. Empowered Funds LLC increased its stake in shares of IDEXX Laboratories by 6.6% in the 1st quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock worth $646,000 after acquiring an additional 95 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of IDEXX Laboratories in the 2nd quarter worth about $265,000. Jump Financial LLC increased its stake in shares of IDEXX Laboratories by 1,006.4% in the 2nd quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock worth $2,967,000 after acquiring an additional 5,032 shares in the last quarter. Cary Street Partners Financial LLC bought a new position in shares of IDEXX Laboratories in the 2nd quarter worth about $164,000. Finally, Sei Investments Co. increased its stake in shares of IDEXX Laboratories by 218.7% in the 2nd quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock worth $64,678,000 after acquiring an additional 82,755 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Up 1.6%

NASDAQ:IDXX opened at $570.00 on Tuesday. The firm has a market cap of $44.96 billion, a P/E ratio of 41.97, a P/E/G ratio of 3.07 and a beta of 1.56. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The firm has a 50-day simple moving average of $563.07 and a two-hundred day simple moving average of $625.43.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. UBS Group reduced their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Stifel Nicolaus reduced their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. Citigroup initiated coverage on shares of IDEXX Laboratories in a research note on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Finally, Wall Street Zen upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.